Last update 12 Dec 2024

TGRX-814

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TGRX 814, TGRX-814, TGRX814
Target
Bcl-2 x Bcl-xl
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors), Bcl-xl inhibitors(Apoptosis regulator Bcl-X inhibitors)
Therapeutic Areas
NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases
Active Indication
Acute Myeloid LeukemiaAdult Acute Lymphocytic LeukemiaMyelodysplastic Syndromes+ [1]
Inactive Indication-
Originator Organization
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
Active Organization
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with TGRX-814
CTR20240015 / RecruitingPhase 1/2
一项评价 TGRX-814 单药及联合疗法治疗血液系统恶性肿瘤 患者的安全性、耐受性、药代动力学和初步疗效的单臂、开放、 剂量递增及扩展的 I/II 期临床试验
[Translation] A single-arm, open-label, dose-escalation and expansion Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-814 monotherapy and combination therapy in patients with hematological malignancies
NCT06206174 / RecruitingPhase 1/2
A Single-arm, Open-label, Dose Escalation and Expansion Phase I/II Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-814 Monotherapy and Combination Therapy in Patients With Hematological Malignancies
100 Clinical Results associated with TGRX-814
Login to view more data
100 Translational Medicine associated with TGRX-814
Login to view more data
100 Patents (Medical) associated with TGRX-814
Login to view more data
100 Deals associated with TGRX-814
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 2
CN
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
06 Mar 2024
Adult Acute Lymphocytic LeukemiaPhase 2
CN
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
06 Mar 2024
Myelodysplastic SyndromesPhase 2
CN
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
06 Mar 2024
Non-Hodgkin LymphomaPhase 2
CN
Shenzhen TargetRx, Inc.Shenzhen TargetRx, Inc.Startup
06 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free